Ipilimumab for patients with relapse after allogeneic transplantation

New England Journal of Medicine

Volumn 375, Issue 2, 2016, Pages 143-153

  Davids, Matthew S ^a   Kim, Haesook T ^a   Bachireddy, Pavan ^a,f   Costello, Caitlin ^h   Liguori, Rebecca ^a   Savell, Alexandra ^a   Lukez, Alexander P ^a   Avigan, David ^a   Chen, Yi Bin ^b   McSweeney, Peter ⁱ   LeBoeuf, Nicole R ^c   Rooney, Michael S ^g   Bowden, Michaela ^e   Zhou, Chensheng W ^e   Granter, Scott R ^d   Hornick, Jason L ^d   Rodig, Scott J ^d   Hirakawa, Masahiro ^a   Severgnini, Mariano ^a   Stephen Hodi, F ^a   Wu, Catherine J ^a,f   Ho, Vincent T ^a   Cutler, Corey ^a   Koreth, John ^a   Alyea, Edwin P ^a   Antin, Joseph H ^a   Armand, Philippe ^a   Streicher, Howard ^j   Ball, Edward D ^h   Ritz, Jerome ^a   Bashey, Asad ^k   Soiffer, Robert J ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c Dana Farber and Brigham and Women's Cancer Center ^*  (United States)

^d Dana Farber and Brigham and Women's Cancer Center   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^g Neon Therapeutics Inc   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁱ Rocky Mountain Blood and Marrow Transplant Program   (United States)

^j NATIONAL CANCER INSTITUTE   (United States)

^k NORTHSIDE HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID; IPILIMUMAB; MONOCLONAL ANTIBODY;

ACUTE KIDNEY FAILURE; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; CANCER MORTALITY; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COLITIS; CORNEA ULCER; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS TUMOR EFFECT; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INDUCTION CHEMOTHERAPY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; NONHODGKIN LYMPHOMA; OPEN STUDY; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VOLUME; ALLOTRANSPLANTATION; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; LEUKEMIA; LYMPHOMA; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PATHOLOGY; RECURRENT DISEASE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CD4 LYMPHOCYTE COUNT; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA; LYMPHOMA; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; RECURRENCE; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

EID: 84978402706     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1601202     Document Type: Article

References (22)

1. Antin JH. Graft-versus-leukemia: no longer an epiphenomenon. Blood 1993; 82:2273-7.
2. Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoi-etic cell transplantation for patients older than 50 years of age. Blood 2005; 105: 1810-4.
3. Mielcarek M, Storer BE, Flowers ME, Storb R, Sandmaier BM, Martin PJ. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007;13:1160-8.
4. Thanarajasingam G, Kim HT, Cutler C, et al. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013; 19: 1713-8.
5. Soiffer RJ. Donor lymphocyte infusions for acute myeloid leukaemia. Best Pract Res Clin Haematol 2008; 21: 455-66.
6. Armand P. Immune checkpoint blockade in hematologic malignancies. Blood 2015;125:3393-400.
7. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. Journal Immunol 2003;171:1272-7.
8. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Sharpe AH, Vallera DA. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo allo responses in murine recipients of MHC disparate T cells. J Immunol 1999; 162: 6368-77.
9. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997;7:445-50.
10. Kuhns MS, Epshteyn V, Sobel RA, Allison JP. Cytotoxic T lymphocyte anti-gen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells. Proc Natl Acad Sci USA 2000; 97: 12711-6.
11. Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after alloge-neic hematopoietic cell transplantation. Blood 2009;113:1581-8.
12. Zhou J, Bashey A, Zhong R, et al. CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells. Biol Blood Marrow Transplant 2011;17:682-92.
13. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825-8.
14. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-56.
15. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-64.
16. Vago L, Kimi Perna S, Zanussi M, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 2009;361:478-88.
17. Toffalori C, Cavattoni I, Deola S, et al. Genomic loss of patient-specific HLA in acute myeloid leukemia relapse after well-matched unrelated donor HSCT. Blood 2012;119:4813-5.
18. Bachireddy P, Hainz U, Rooney M, et al. Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood 2014;123:1412-21.
19. Koc Y, Miller KB, Schenkein DP, Daoust P, Sprague K, Berkman E. Extra-medullary tumors of myeloid blasts in adults as a pattern of relapse following allogeneic bone marrow transplantation. Cancer 1999; 85: 608-15.
20. Yoshihara S, Ando T, Ogawa H. Extra-medullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: an easily overlooked but significant pattern of relapse. Biol Blood Marrow Transplant 2012; 18: 1800-7.
21. Thome JJ, Yudanin N, Ohmura Y, et al. Spatial map of human T cell compart-mentalization and maintenance over decades of life. Cell 2014; 159: 814-28.
22. Koguchi Y, Hoen HM, Bambina SA, et al. Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilim-umab. Cancer Res 2015; 75: 5084-92.